DanielFMandriMD

Psychiatry • Miami, FL

Physician

Join to view full profile

Dr. Mandri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mandri's full profile

Already have an account?

Office
8785 SW 165th Avenue
Suite 200
Miami, FL 33193
Phone+1 786-209-2160

Fax+1 786-209-2160
Is this information wrong?

Education & Training

University of Miami/Jackson Health SystemResidency, Psychiatry, 1980 - 1983
Advocate Health Care/Advocate Christ Medical CenterInternship, Internal Medicine, 1979 - 1980
Universidad Central del Este Facultad de MedicinaClass of 1977

Certifications & Licensure

FL State Medical License 1979 - 2026
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Physician's Recognition Award American Medical Association
Certificate of Commendation Mental Health Association of Dade County
Certificate of Appreciation for Exemplary Service Admission Committee Herbert. Wertheim College of Medicine Florida International University

Publications & Presentations

PubMed

94 citations
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
Christopher F. O'Brien, Roland Jimenez, Robert A. Hauser, Stewart A. Factor, Joshua Burke, Daniel Mandri, Julio C. Castro‐Gayol> ;Movement Disorders. 2015 Oct 1

Research History

Principal investigatorProtocol xxxxx: A study to assess effectiveness, safety and health related outcomes of xxxxx for the treatment of Pseudobulbar affect in nursing home patients.
Principal InvestigatorProtocol xxxxx: A phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of xxxxx for the treatment of agitation in patients with dementia of the Alzheimer’s type.
Principal investigatorProtocol xxxxx: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of xxxxx for the Treatment of Tardive Dyskinesia.

Professional Memberships

American Psychiatric Association
Fellow
The New York Academy of Science
Member
The Royal Society of Medicine
Member
World Psychiatric Association
Member

Other Languages

Spanish

Hospital Affiliations

Baptist Hospital of MiamiMiami, Florida
Homestead HospitalHomestead, Florida
South Miami HospitalMiami, Florida
Doctors HospitalMiami, Florida